Shots:
- ARCH Venture Partners is a leading US-based venture capital firm recognized for backing bold science and building category-defining companies across biotechnology, life sciences, and transformational healthcare, with a strong focus on company creation
- In 2024, ARCH completed 31 investments from Seed to Series A–F and beyond, including late-stage and private rounds. The firm backed innovators such as nChroma Bio, Maze Therapeutics, Metsera, Be Biopharma, and Seaport Therapeutics, with disclosed investments of approximately $5.44B, demonstrating its ability to support companies across the full lifecycle
- ARCH targets high-need therapeutic areas including oncology, genetic diseases, neurology, metabolic disorders, and immunology, while advancing next-generation technologies such as gene editing, cell and gene therapies, RNA-based medicines, precision diagnostics, and platform biotechnologies
Welcome to the December edition of Know Your Investor, highlighting visionary investors driving healthcare and life sciences innovation. For a curated report on a specific investor or venture capital firm, connect with us at connect@pharmashots.com
Founded in 1986, ARCH Venture Partners is a US-based venture capital firm distinguished for backing and building companies rooted in cutting-edge academic science. Operating across early- to late-stage private and public investments, ARCH supports ventures with capital ranging from as little as $50K to hundreds of millions, reflecting its flexibility and long-term conviction.
With a mission to address significant unmet medical needs, ARCH partners with founders developing transformative therapies and breakthrough technologies. Its diversified portfolio spans biotechnology, life sciences, and healthcare innovation, supporting companies from inception and company creation through commercialization and the public markets, cementing ARCH’s role as a cornerstone investor in science-driven healthcare advancement.
In 2024, ARCH Venture Partners remained highly active across the investment spectrum, participating in Series Seed, Series A–F and beyond, as well as late-stage private rounds.
- nChroma Bio
- Maze Therapeutics
- Metsera
- Be Biopharma
- Seaport Therapeutics
Highlighting the year’s activity, ARCH made its largest disclosed investment of 2024 with a $1B commitment to Xaira Therapeutics, underscoring the firm’s conviction in platform-driven companies with the potential to redefine therapeutic development.
ARCH Venture Partners concentrates on early- to late-stage companies advancing science-driven therapies and scalable platform technologies, with a strong emphasis on innovation emerging from the US biotechnology and life sciences ecosystem. The firm partners with teams translating foundational science into transformative healthcare solutions, reinforcing its position as a long-term, conviction-driven investor.
Therapeutic Areas of Focus (2024):
- Oncology
- Genetic & Rare Diseases
- Neurologic Disorders
- Metabolic & Endocrine Disorders
- Autoimmune & Inflammatory Diseases
- Cardiovascular Diseases
Technological Focus (2024):
- Gene therapies
- Cell therapies
- Gene therapies
- RNA Therapeutics
- Protein
- Antibody
- Small molecules
In 2024:
- Total Companies Invested: 28
- Series A: 41.93% of investments
- Private Funding: 16.12% of investments
Key Investments in 2024:
- $1B Series A - Xaira Therapeutics
- $900M Series A - Curie.Bio
- $425M Series A - Areteia Therapeutics
The table below depicts the top 5 investments made by ARCH Venture Partners in 2024:
Note: (For a complete report, reach out to us at connect@pharmashots.com with the subject line “ARCH Venture Partners” and if you want a report on investments made in 2025 by “ARCH Venture Partners” reach out to us with the subject line “ARCH Venture Partners 2025”)
Related Post: Know Your Investor: ARCH Venture Partners (October’24 Edition)
